Boston University Chobanian & Avedisian School of Medicine

SCOPE of Pain can be used to count toward the DEA licensure 8-hour training requirement as noted in their 3/27/2023 communication as it aligns with SAMHSA's content recommendations required by the 2022 Medication Access and Training Expansion (MATE) Act.

DEA Questions Answered (PDF)

Core curriculum

Live conferences


Overview

Join us for a SCOPE of Pain Live Webinar or Meeting!

These 2½- to 3-hour meetings will address the core SCOPE of Pain content, and often include additional content specific to the municipality, region, state, and/or institution serving as collaborating partner.

GET STARTED NOW! Select a conference

Course Director

Daniel P. Alford, MD, MPH
Professor of Medicine
Associate Dean, Continuing Medical Education

Boston University Chobanian & Avedisian School of Medicine

What is this training about?

SCOPE of Pain is a continuing medical education/continuing nursing education activity designed to help you safely and effectively manage patients with acute and/or chronic pain, when appropriate, with opioid analgesics. Through the case of Michelle Jones, a 36-year-old who has a displaced right femoral neck fracture due to a motor vehicle crash, you'll learn how to:

  1. Optimize safety when prescribing opioids for acute pain
  2. Determine when opioid analgesics are indicated for chronic pain
  3. Assess pain and prescription opioid misuse risk
  4. Educate patients about opioid risks and realistic benefits
  5. Monitor patients on opioid therapy for benefits and harms
  6. Assess and manage worrisome opioid-taking behaviors
  7. Safely taper long-term opioid therapy
  8. Identify and manage patients with an opioid use disorder

Who is this for?

Physicians, nurse practitioners, registered nurses, physician assistants, nurses, dentists, pharmacists, and allied health professionals whose practices manage acute and chronic pain.

Partners

This activity was planned in collaboration with the Federation of State Medical Boards.

Accreditation

Credit hours will vary depending upon the length of the meeting. Please see registration page for maximum credit amounts.

Jointly Accredited Provider with Commendation | Interprofessional Continuing Education

In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

These live activities have been approved for AMA PRA Category 1 Credit™.

AAFP Credit System Approved

The AAFP has reviewed SCOPE of Pain: Safer/Competent Opioid Prescribing Education, and deemed it acceptable for AAFP credit. Term of approval is from 10/17/2023 to 09/20/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

acpe

This activity is approved for 2.5 CPE credit(s) under ACPE universal activity number(s):

Activity date Universal activity number (UAN)
Mar 21, 2024 JA0000185-0000-24-003-L08-P
Apr 09, 2024 JA0000185-0000-24-004-L08-P
May 14, 2024 JA0000185-0000-24-005-L08-P
Jun 13, 2024 JA0000185-0000-24-006-L08-P
Jul 16, 2024 JA0000185-0000-24-007-L08-P
Aug 14, 2024 JA0000185-0000-24-008-L08-P
Sep 19, 2024 JA0000185-0000-24-009-L08-P

The activity is available for credit claiming for up to 60 days after the date of the activity.

Disclosure of support

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).

Get Adobe Acrobat Reader DC.png

Boston University Federation of State Medican Boards